SynthesisJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists2024
Late Endograft Migration After Thoracic Endovascular Aortic Repair: A Systematic Review and Meta-analysis.
Synthesis in Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Preserve or Cover? The Isolated Left Vertebral Artery in Totally Endovascular Zone 2 TEVAR.Reviews in cardiovascular medicine · 2026Article
- Management of Late TEVAR Migration Using a Novel Branched Endograft: First Western Experience.JACC. Case reports · 2026Article
- Dedicated Single-Branch Platforms for Totally Endovascular Zone 2 TEVAR with LSA Revascularization: A Comparison of Castor/Cratos and Gore TAG Thoracic Branch Endoprosthesis.Journal of clinical medicine · 2026Review
- Clinically silent early proximal seal failure with suspected interval distal endograft displacement after hybrid zone 2 thoracic endovascular aortic repair in severe arch tortuosity: a case report with 1-year follow-up.Frontiers in medicine · 2026Article
- Early Outcomes of Zone 2 Thoracic Endovascular Aortic Repair with an Integrated Branch Stent Graft for the Left Subclavian Artery: Evidence from a Western Centre.EJVES vascular forum · 2026Article
- Aortic and cardiovascular remodelling after thoracic endovascular aortic repair for blunt traumatic aortic injury in younger patients: A narrative review of physiological and clinical outcomes.Experimental physiology · 2026Review
- Recent Patents of Stent Grafts for Intravascular Aortic Repair.Recent patents on biotechnology · 2026Review
- Endovascular repair of subacute complicated type B aortic dissections using the Castor branched endograft and the STABILISE technique.Journal of vascular surgery cases and innovative techniques · 2025Article
- Dynamic Morphology of the Ascending Aorta and Its Implications for Proximal Landing in Thoracic Endovascular Aortic Repair.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe objective of this systematic review was to report the cumulative incidence of endograft migration (EM), as well as the morbidity, reintervention rates, and mortality related to EM. This study aimed to provide evidence-based data on patient-relevant sequelae of EM after thoracic endovascular aortic repair (TEVAR) performed using contemporary aortic endografts. MATERIALS AND
methodsA systematic electronic search of literature in MEDLINE (via PubMed), Web of Science, and Cochrane Central Register of Controlled Trials was performed. The pooled synthesis of outcomes was performed using the inverse variance method.
resultsSeven prospective non-randomized and 4 retrospective studies, including a total of 1783 patients presenting 70 EMs, were considered for the quantitative analysis. The pooled rate of EM was 4% (95% CI, 2%-7%; range, 0.2%-11%; I2=82%); pooled morbidity rate was 31% (95% CI, 12%-59%; range, 0%-100%; I2=64%) and pooled reintervention rate was 32% (95% CI, 15%-56%; range, 0%-100%; I2=55%). The pooled mortality rate due to EM was 5% (95% CI, 1%-21%; range, 0%-40%; I2=24%).
conclusionFor the first time, this meta-analysis provides pooled reference estimates of EM after TEVAR. Thus, the results hold the potential to further characterize EM after TEVAR. The clinical relevance of EM is underlined by its association with high rates of endoleak-related morbidity, reintervention, and mortality. Close standardized surveillance after TEVAR for early detection of EM and prophylaxis of its sequelae is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.